Microbial Biofilms pp 187-201

Part of the Methods in Molecular Biology book series (MIMB, volume 1147)

In Vitro Screening of Antifungal Compounds Able to Counteract Biofilm Development

Protocol

Abstract

Fungi are able to grow as a single-species or a more complex biofilm attached to inert surfaces (catheters…) or tissues (lung…). This last form is a microbial niche which must be considered as a major risk factor of developing a human fungal infection. Nowadays, only a few therapeutic agents have been shown to be active against fungal biofilms in vitro and/or in vivo. So there is a real need to find new anti-biofilm molecules. Here we describe in detail some rapid, 96-well microtiter plate-based methods, for the screening of compounds with anti-biofilm activity against Candida spp. yeasts. Two approaches will be considered: prophylactic or curative effects of the tested compounds by producing biofilms on two supports – polystyrene well surfaces and catheter sections.

Key words

Biofilms Candida spp. Antifungal compounds Catheters Microtiter plates Fungal infections Colorimetric assay XTT 

References

  1. 1.
    Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322PubMedCrossRefGoogle Scholar
  2. 2.
    Donlan RM (2002) Biofilms: microbial life on surfaces. Emerg Infect Dis 8:881–890PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Kuhn DM, George T, Chandra J et al (2002) Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46:1773–1780PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Mukherjee PK, Chandra J (2004) Candida biofilm resistance. Drug Resist Updat 7:301–309PubMedCrossRefGoogle Scholar
  5. 5.
    Chandra J, Kuhn DM, Mukherjee PK et al (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183:5385–5394PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    LaFleur MD, Kumamoto CA, Lewis K (2006) Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50:3839–3846PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Uppuluri P, Nett J, Heitman J et al (2008) Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52:1127–1132PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Cornely OA, Bassetti M, Calandra T et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19–37PubMedCrossRefGoogle Scholar
  9. 9.
    Ullmann AJ, Akova M, Herbrecht R et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53–67PubMedCrossRefGoogle Scholar
  10. 10.
    Cateau E, Berjeaud JM, Imbert C (2011) Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int J Antimicrob Agents 37:380–384PubMedCrossRefGoogle Scholar
  11. 11.
    Toulet D, Debarre C, Imbert C (2012) Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? J Antimicrob Chemother 67:430–432PubMedCrossRefGoogle Scholar
  12. 12.
    Mukherjee PK, Long L, Kim HG et al (2009) Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 33:149–153PubMedCrossRefGoogle Scholar
  13. 13.
    Uppuluri P, Srinivasan A, Ramasubramanian A et al (2011) Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother 55:3591–3593PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Seidler M, Salvenmoser S, Müller FMC (2010) Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model. FEMS Yeast Res 10:492–495PubMedCrossRefGoogle Scholar
  15. 15.
    Liu W, Li L, Sun Y et al (2012) Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro. Antimicrob Agents Chemother 56:6414–6416PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Fiori B, Posteraro B, Torelli R et al (2011) In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother 55:3031–3035PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167–193PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Hawser SP, Douglas LJ (1994) Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 62:915–921PubMedCentralPubMedGoogle Scholar
  19. 19.
    Jin Y, Yip HK, Samaranayake YH et al (2003) Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 41:2961–2967PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Laboratory of ecology and biology of the interactions, Faculty of Medicine PharmacyUniversity of Poitiers, UMR CNRS 7267PoitiersFrance

Personalised recommendations